Nato Pharma said the US Food and Drug Administration (USFDA) issued the seven observations after it inspected the active pharmaceutical ingredient (API) division unit in Manali, Chennai, from November 17 to November 21, 2025.
Nato Pharma said the US Food and Drug Administration (USFDA) issued the seven observations after it inspected the active pharmaceutical ingredient (API) division unit in Manali, Chennai, from November 17 to November 21, 2025.